Stock comparison
IDEXX Laboratories
Novartis AG
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
NVS
Novartis AG
Market cap
$290.64B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | NVS | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 62C | IDXX |
| Benjamin Graham | 80A | 69B | IDXX |
| Philip Fisher | 75B | 53C | IDXX |
| Peter Lynch | 71B | 35D | IDXX |
| Joel Greenblatt | 83C | 46D | IDXX |
| Charlie Munger | 87A | 69C | IDXX |
| Terry Smith | 84A | 66B | IDXX |
Side-by-side metrics
| Metric | IDXX | NVS |
|---|---|---|
| Market cap | $44.06B | $290.64B |
| P/E (TTM) | 39.0x | 21.3x |
| EV/EBIT | 31.6x | 19.2x |
| ROIC (TTM) | 40.66% | 14.89% |
| Gross margin | 62.05% | 75.13% |
| Net margin | 24.63% | 24.31% |
| Revenue CAGR 5y | 7.56% | 5.66% |
| EPS CAGR 5y | 10.79% | -9.29% |
| Debt / Equity | 0.7x | 1.2x |
| Dividend yield | 0.0% | 3.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -9.29%+186%
- ROIC (TTM)40.66%vs 14.89%+63%
- Debt / Equity0.7xvs 1.2x+43%
- Revenue CAGR 5y7.56%vs 5.66%+25%
NVS leads on
- Dividend yield3.12%vs 0.0%+100%
- Market cap$290.64Bvs $44.06B+85%
- P/E (TTM)21.3xvs 39.0x+45%
- EV/EBIT19.2xvs 31.6x+39%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.